Last updated: August 27, 2026
CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-01832, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Teva's proposed generic version of Evomela, an injectable melphalan hydrochloride product. CyDex asserted patents covering a Captisol-enabled melphalan formulation after receiving Teva's Paragraph IV certification. The case formed part of the broader patent estate protecting Evomela's reformulated injectable dosage form rather than conventional melphalan products. [1]
What drug and formulation were involved in CyDex v. Teva?
The litigation involved melphalan hydrochloride for injection, marketed as Evomela by Spectrum Pharmaceuticals and later associated with Acrotech Biopharma. Evomela is an intravenous formulation of melphalan used primarily in conditioning treatment before autologous stem-cell transplantation in multiple myeloma and in the palliative treatment of multiple myeloma.
The product uses sulfobutyl ether beta-cyclodextrin sodium, commercially known as Captisol, to improve the stability and solubility of melphalan. CyDex developed Captisol and owned patents directed to the formulation technology.
| Item |
Detail |
| Brand drug |
Evomela |
| Active ingredient |
Melphalan hydrochloride |
| Dosage form |
Intravenous powder for reconstitution |
| NDA holder at launch |
Spectrum Pharmaceuticals |
| Captisol developer |
CyDex Pharmaceuticals |
| Regulatory pathway |
ANDA-based generic challenge |
| Court |
U.S. District Court for the District of Delaware |
| Case |
No. 1:17-cv-01832 |
| Defendant |
Teva Pharmaceuticals USA, Inc. |
| Litigation type |
Hatch-Waxman patent infringement action |
FDA approved Evomela in October 2016 under NDA 208587. The product was a reformulated version of melphalan intended to address the instability and handling limitations associated with older formulations. [2]
What patents protect Evomela and Captisol-enabled melphalan?
CyDex's asserted patent estate covered stabilized melphalan compositions containing cyclodextrin derivatives. The central patents associated with Evomela included U.S. Patent Nos. 9,756,673 and 9,895,390. The patents were directed to pharmaceutical compositions and methods involving melphalan and Captisol-type excipients. [1,3]
The estate was commercially significant because a generic applicant could avoid the older melphalan patents yet still face infringement exposure if its ANDA product used the same stabilized formulation architecture.
Key patent characteristics
| Patent |
General subject matter |
Relevance to Evomela |
| U.S. Patent No. 9,756,673 |
Stabilized melphalan pharmaceutical compositions |
Direct formulation protection |
| U.S. Patent No. 9,895,390 |
Related melphalan and cyclodextrin formulation claims |
Follow-on formulation protection |
| Captisol platform patents |
Sulfobutyl ether beta-cyclodextrin compositions and uses |
Broader excipient and manufacturing position |
The practical protection came from formulation claims rather than from the basic discovery of melphalan. Melphalan itself is an old cytotoxic compound. The commercial value resided in the improved injectable formulation and the ability to obtain regulatory approval for a more stable product.
Why did CyDex sue Teva under the Hatch-Waxman Act?
Teva filed an ANDA seeking approval to market a generic melphalan hydrochloride injection. Its Paragraph IV certification stated that the relevant patents were invalid, unenforceable, or would not be infringed by Teva's proposed product.
CyDex responded under 35 U.S.C. § 271(e)(2), which treats the submission of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement. The statutory claim allows the patent owner to litigate infringement before commercial launch.
The filing of the complaint triggered the statutory 30-month stay on FDA approval of Teva's ANDA, subject to court orders and statutory exceptions. The case therefore had two immediate business effects:
- It delayed FDA approval of Teva's generic product.
- It preserved CyDex's ability to seek an injunction before generic commercialization.
What were the principal infringement and validity issues?
The central question was whether Teva's proposed formulation met the limitations of the asserted claims. The likely disputed issues involved:
- The identity and concentration of the cyclodextrin excipient.
- The amount of melphalan hydrochloride in the formulation.
- Stability during storage and reconstitution.
- Whether the claims required particular pH, concentration, or degradation limits.
- Whether the claims were enabled across their full scope.
- Whether the claimed formulation was obvious in light of earlier melphalan products and cyclodextrin technology.
Formulation-infringement risk
Formulation cases often turn on the ANDA's detailed product description rather than the commercial label alone. If Teva's ANDA used Captisol or a materially equivalent sulfobutyl ether beta-cyclodextrin in the claimed concentration range, CyDex had a direct infringement theory.
The risk was higher if:
- Teva's product copied the same reconstitution behavior.
- The ANDA specified the same excipient class and concentration.
- The formulation delivered the same stability profile.
- Teva relied on Evomela's clinical and pharmaceutical characteristics to support approval.
CyDex did not need to prove that Teva had already sold the product. Under the Hatch-Waxman framework, the ANDA submission itself supplied the jurisdictional infringement act.
Invalidity risk
Teva's strongest potential defenses were obviousness and claim construction. Melphalan was well known, and cyclodextrins had established use as solubilizing and stabilizing agents. Teva could argue that a skilled formulation scientist would have combined melphalan with a known cyclodextrin derivative.
CyDex's counterargument was that the claimed combination solved a specific instability problem and produced a commercially useful formulation with properties that were not predictable from the prior art. Evidence of unexpected stability, improved shelf life, reduced degradation, or successful pharmaceutical development could support nonobviousness.
The age of melphalan did not eliminate patent value. In pharmaceutical formulation litigation, the relevant question is usually whether the claimed combination, process, or performance characteristic was obvious, not whether the active ingredient was old.
What was the litigation status and outcome?
The publicly available docket identifies the action as a Delaware Hatch-Waxman case filed in 2017. The case was resolved without a reported merits opinion establishing that Teva's proposed product infringed or that the asserted patents were invalid. The docket record does not establish a public trial judgment determining the full scope of the patents against Teva. [1]
The absence of a reported invalidity or noninfringement judgment is commercially important. It means the case did not create a broad judicial precedent eliminating the Evomela formulation estate. It also means that the principal commercial issue was likely resolved through procedural termination or agreement rather than through a fully litigated final judgment.
Public settlement terms, including any authorized generic provision, launch date, royalty arrangement, or patent-license scope, should not be treated as established unless disclosed in the docket or a regulatory filing. A confidential Hatch-Waxman settlement can end the litigation while leaving the underlying patent claims untested.
When could Teva launch a generic melphalan product?
A Teva launch could occur through one of several mechanisms:
- Expiration or invalidation of the asserted patents.
- A settlement license permitting entry on an agreed date.
- A product redesign that avoids the asserted formulation claims.
- A court finding of noninfringement.
- A later regulatory approval after the statutory stay expired.
Because Evomela's patent protection was formulation-based, a non-infringing alternative would have been technically more difficult than a simple substitution of an inactive ingredient. Teva could attempt to use a different stabilizer, a different concentration, or a different manufacturing and reconstitution process. That strategy would carry regulatory comparability and product-development risks.
What was the Orange Book and FDA significance?
FDA's Orange Book lists patents submitted by NDA holders for approved drug products. The listing of formulation patents can delay ANDA approval when a generic applicant files a Paragraph IV certification and the patent owner brings suit within the statutory period.
For Evomela, the relevant regulatory value was tied to:
- FDA approval of the Captisol-enabled melphalan formulation.
- Patent listings covering the approved formulation.
- The 30-month stay created by CyDex's timely infringement action.
- Teva's ability to challenge listed patents through the ANDA process.
FDA approval of the reference product did not independently validate the patents. Regulatory approval and patent enforceability are separate questions. The FDA determines whether the generic meets statutory approval requirements; the court determines infringement, validity, and enforceability.
How strong was CyDex's patent estate?
CyDex's estate was stronger against close formulation copies than against substantially redesigned products.
Strengths
- It protected a reformulated product containing an old active ingredient.
- Captisol was a defined excipient platform with proprietary manufacturing and composition technology.
- The patents could block a generic that used the same stabilizing approach.
- The formulation solved a recognized pharmaceutical-development problem.
- Evomela had regulatory approval and commercial use before the generic challenge.
Weaknesses
- Melphalan was an established drug.
- Cyclodextrins were known pharmaceutical excipients.
- Obviousness arguments could combine prior art on melphalan with prior art on cyclodextrin stabilization.
- The commercial label might not reveal every claim limitation, creating proof issues.
- A generic manufacturer could pursue a different formulation.
The estate was therefore best characterized as a targeted formulation barrier, not a fundamental active-ingredient monopoly.
Which companies were competing in the melphalan market?
The principal commercial competition involved the legacy melphalan injection market and the newer Evomela formulation.
| Product |
Company or commercial sponsor |
Formulation position |
| Evomela |
Spectrum Pharmaceuticals, later Acrotech |
Captisol-enabled melphalan formulation |
| Conventional melphalan injection |
Multiple manufacturers over time |
Older formulation technology |
| Proposed Teva product |
Teva Pharmaceuticals |
ANDA product challenged by CyDex |
Biosimilar risk was not material. Melphalan is a small-molecule drug, so competition proceeds through ANDAs and generic-drug litigation rather than the biosimilar pathway under the Public Health Service Act.
What revenue exposure did the case create?
The litigation threatened Evomela's premium over conventional melphalan. A generic launch could affect:
- Hospital and oncology purchasing contracts.
- Formulary placement.
- Average selling price.
- Reimbursement margins.
- Distributor inventory.
- Market share among transplant centers.
- Licensing and royalty economics for Captisol.
The commercial risk was greater because Evomela competed in a price-sensitive institutional market. A successful generic could discount materially while using the same clinical indication and route of administration.
CyDex's economic interest was not limited to Evomela sales. A successful formulation patent could support licensing revenue from other Captisol-enabled products and strengthen negotiating leverage with additional generic applicants.
What patent litigation affects generic launch risk for Evomela?
The Teva action should be analyzed together with any other ANDA suits involving Evomela patents. Multiple applicants can create separate litigation tracks, and a settlement with one applicant does not necessarily establish a market-wide launch date.
The key launch-risk indicators are:
- Whether all Orange Book-listed patents were challenged.
- Whether any applicant obtained a final invalidity or noninfringement ruling.
- Whether settlements permit earlier entry.
- Whether a generic can avoid the asserted claims through formulation redesign.
- Whether FDA approval remains blocked by the statutory stay or pediatric exclusivity.
- Whether additional unlisted patents create commercial but not Hatch-Waxman enforcement risk.
Key Takeaways
- CyDex v. Teva was a Hatch-Waxman case involving Teva's proposed generic melphalan hydrochloride injection.
- The dispute centered on Evomela's Captisol-enabled formulation, not on ownership of the basic melphalan molecule.
- U.S. Patent Nos. 9,756,673 and 9,895,390 were central formulation patents associated with the Evomela patent estate.
- CyDex's strongest position was against products closely copying the Captisol-enabled formulation.
- Teva's principal defenses would have involved noninfringement, obviousness, enablement, and claim construction.
- The case did not produce a reported merits judgment broadly invalidating the asserted formulation patents.
- Generic competition presented a material risk to Evomela pricing, hospital contracts, and Captisol-related licensing economics.
- Biosimilar analysis is not applicable because melphalan is a small molecule regulated through the ANDA pathway.
FAQs
What is CyDex Pharmaceuticals known for in drug patent litigation?
CyDex is known for Captisol, a sulfobutyl ether beta-cyclodextrin excipient used to improve the solubility and stability of pharmaceutical products.
Did the Teva case concern conventional melphalan?
No. The dispute concerned Teva's proposed generic injectable product and the patented stabilized formulation associated with Evomela.
Was Evomela protected by an active-ingredient patent?
The principal commercial protection at issue was formulation protection. Melphalan itself was an established active ingredient.
Could Teva avoid the patents by changing the excipient?
Potentially, but a redesign would need to avoid the asserted claim limitations while still satisfying FDA requirements for quality, stability, bioequivalence, and injectable-product performance.
Is a generic melphalan launch a biosimilar event?
No. Melphalan is a small-molecule drug. Generic entry requires an ANDA, not a biosimilar application.
References
- U.S. District Court for the District of Delaware. (2017). CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-01832. PACER docket record.
- U.S. Food and Drug Administration. (2016). Evomela (melphalan hydrochloride) injection: Approval history and prescribing information.
- U.S. Patent and Trademark Office. (2017-2018). U.S. Patent Nos. 9,756,673 and 9,895,390. Patent Center.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- 35 U.S.C. § 271(e)(2). Action for patent infringement based on submission of an ANDA.
